<?xml version="1.0" encoding="UTF-8"?>
<p>The Coalition for Epidemic Preparedness Innovations (CEPI) recently announced that three programs aimed to develop COVID-19 vaccines, by utilizing established vaccine platforms, have started [
 <xref rid="B210-ijerph-17-05648" ref-type="bibr">210</xref>]. In addition, CEPI already financed the company Moderna, Inc. to compare mRNA therapeutics and vaccines, allowing the release of the first batch of mRNA-1273 in February 2020, which is an mRNA vaccine against SARS-CoV-2 ready for phase I study in the United States. Available online: 
 <uri xlink:href="https://investors.modernatx.com/news-releases/news-release-details/moderna-ships-mrna-vaccine-against-novel-coronavirus-mrna-1273" xmlns:xlink="http://www.w3.org/1999/xlink">https://investors.modernatx.com/news-releases/news-release-details/moderna-ships-mrna-vaccine-against-novel-coronavirus-mrna-1273</uri> (accessed on 24 February 2020).
</p>
